This fact sheet is for men who would like to know more about bisphosphonates to relieve bone pain or bone weakness when prostate cancer has spread to the bones.

Last updated: May 2018
To be reviewed: November 2020


  • Abrahamsen B, Brask-Lindemann D, Rubin KH, Schwarz P. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. BoneKEy Reports. 2014 Sep 3;3:574.

  • Attar S, Steffner RJ, Avedian R, Hussain WM. Surgical intervention of nonvertebral osseous metastasis. Cancer Control. 2012;19(2):113–121.

  • Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients: a systematic review of randomized controlled trials. Supportive Care in Cancer. 2012;20(2):221–33.

  • Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, et al. Bone health in the elderly cancer patient: A SIOG position paper. Cancer Treatment Reviews. 2016 Dec;51:46–53.

  • British Uro-oncology Group (BUG), British Association of Urological Surgeons (BAUS). Multi-disciplinary Team (MDT) Guidance for Managing Prostate Cancer. 2013

  • Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–66.

  • Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. British Journal of Cancer. 2011 Nov 8;105:S52–73.

  • Department of Health. UK Chief Medical Officers’ Low Risk Drinking Guidelines. 2016

  • Drake MT. Osteoporosis and Cancer. Current Osteoporosis Reports. 2013 Sep;11(3):163–70.

  • Ebeling PR. Osteoporosis in men. New England Journal of Medicine. 2008;358:1474–82.

  • Electronic Medicines Compendium. Actonel 30 mg film-coated tablets - Summary of Product Characteristics. [cited 2017 Jul 12].

  • Electronic Medicines Compendium. Fosamax - Summary of Product Characteristics. [cited 2017 Jul 12].

  • Electronic Medicines Compendium. Zometa 4mg/5ml Concentrate for Solution for Infusion. [cited 2015 Feb 24].

  • Electronic Medicines Compendium. Zometa 4mg/100ml Solution for Infusion - Patient Information Leaflet. [cited 2015 Feb 24].

  • Felice FD, Piccioli A, Musio D, Tombolini V. The role of radiation therapy in bone metastases management. Oncotarget. 2017 Jan 26;8(15):25691–9.

  • Gastanaga VM, Schwartzberg LS, Jain RK, Pirolli M, Quach D, Quigley JM, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Medicine. 2016 Aug;5(8):2091–100.

  • Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011;194(6):301–306.

  • Healthcare Improvement Scotland. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE (Multiple) Technology Appraisal Guidance No 265

  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48.

  • Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.

  • Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Supportive Care in Cancer. 2017

  • Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. Journal of Pain and Symptom Management. 2012 Jan;43(1):96–110.

  • Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research. 2015 Jan;30(1):3–23.

  • Lee S-H, Chan R-C, Chang S-S, Tan Y-L, Chang K-H, Lee MC, et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies. Supportive Care in Cancer. 2014 Feb;22(2):553–60.

  • Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, et al. The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors. J Natl Compr Canc Netw. 2009 Oct;7(Suppl 7):S1–30.

  • Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews. 2017

  • Medicines and Healthcare products Regulatory Agency (MHRA). Bisphosphonates: use and safety. 2014

  • Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012

  • Mohamad NV, Soelaiman I-N, Chin K-Y. A concise review of testosterone and bone health. Clinical Interventions in Aging. 2016 Sep;Volume 11:1317–24.

  • Mundy GR, Roodman GD, Smith MR. New Opportunities for the Management of Cancer-Related Bone Complications. 2009

  • National Institute for Health and Care Excellence. Bisphosphonates for treating osteoporosis. Technology appraisal guidance 464. 2017

  • National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. Clinical guideline 146. 2012

  • National Institute for Health and Care Excellence. Percutaneous cementoplasty for palliative treatment of bony malignancies. IPG179. 2006

  • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014

  • Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):137–45.

  • Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer. 2014

  • Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliative medicine. 2017;31(1):5–25.

  • Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and Benefits of Bisphosphonate Therapies. Journal of Cellular Biochemistry. 2016 Jan;117(1):20–8.

  • Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Research. 2011 May 24;71(11):3889–95.

  • Scottish Medicines Consortium. Zoledronic acid (Zometa®). 2004

  • Serpa Neto A, Tobias-Machado M, Esteves MAP, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate cancer and prostatic diseases. 2012;15(1):36–44.

  • Singh T, Kaur V, Kumar M, Kaur P, Murthy RSR, Rawal RK. The critical role of bisphosphonates to target bone cancer metastasis: an overview. Journal of Drug Targeting. 2015 Jan 2;23(1):1–15.

  • Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Current molecular medicine. 2013;13(4):626–639.

  • Spanou A, Lyritis G, Chronopoulos E, Tournis S. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. Oral Diseases. 2015 Nov;21(8):927–36.

  • Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology. 2008 Apr;5(4):206–19.

  • Thorsen L, Courneya KS, Stevinson C, Fosså SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Supportive Care in Cancer. 2008 Feb 15;16(9):987–97.

  • Todenhöfer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology. 2015;2015:1–9.

  • Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nature Reviews Urology. 2009 Dec 8;7(1):21–30.

  • Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. The Journal of Urology. 2008 Dec;180(6):2314–22.

  • Wenter V, Herlemann A, Fendler WP, Ilhan H, Tirichter N, Bartenstein P, et al. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget. 2017 Apr 21;8(27):44131–40.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication